Heidelberg Pharma to Convene R&D Webinar to Share New Cancer Research Insights

Heidelberg Pharma AG, positioned at the forefront of developing Antibody Drug Conjugates (ADCs) for cancer treatment, has announced an upcoming R&D Webinar on the 23rd of April, 2024. This pivotal event aims to engage investors, analysts, and media representatives in discovering the latest advancements in ADC therapy, specifically targeting multiple myeloma, a type of cancer. Scheduled at 16.00 CEST/15.00 BST, the webinar will spotlight the company's lead clinical candidate, HDP-101.

The webinar promises insightful presentations from Heidelberg Pharma’s executive team and prominent Key Opinion Leaders (KOLs) in the ADC domain. Notably, Rakesh Dixit, PhD, CEO of Bionavigen, and Jonathan Kaufman, MD, Associate Professor at Emory University, are set to contribute. Attendees will receive a comprehensive overview of HDP-101’s clinical developments, particularly its promising efficacy data from Phase I/IIa trials, initially presented at the AACR Annual Meeting in San Diego, California.

Participants will enjoy the opportunity to delve deeper into discussions through a live Q&A session towards the end of the webinar. Heidelberg Pharma invites interested parties to submit questions in advance or sign up for the event through the provided registration link. A recording of the webinar will be available in the press & investor section on the company's website shortly after the live event.